Barings LLC maintained its position in Danaher Corporation (NYSE:DHR) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 71,048 shares of the conglomerate’s stock at the close of the 2nd quarter. Barings LLC’s holdings in Danaher Corporation were worth $6,077,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Financial Enhancement Group LLC grew its holdings in Danaher Corporation by 3.2% in the second quarter. Financial Enhancement Group LLC now owns 59,279 shares of the conglomerate’s stock valued at $5,003,000 after purchasing an additional 1,811 shares during the period. Prudential PLC grew its holdings in Danaher Corporation by 28.1% in the second quarter. Prudential PLC now owns 1,009,309 shares of the conglomerate’s stock valued at $85,176,000 after purchasing an additional 221,300 shares during the period. Cramer Rosenthal Mcglynn LLC grew its holdings in Danaher Corporation by 101.2% in the second quarter. Cramer Rosenthal Mcglynn LLC now owns 1,122,139 shares of the conglomerate’s stock valued at $94,697,000 after purchasing an additional 564,470 shares during the period. Williams Jones & Associates LLC grew its holdings in Danaher Corporation by 6.5% in the second quarter. Williams Jones & Associates LLC now owns 714,531 shares of the conglomerate’s stock valued at $60,299,000 after purchasing an additional 43,348 shares during the period. Finally, Optimum Investment Advisors grew its holdings in Danaher Corporation by 1.8% in the second quarter. Optimum Investment Advisors now owns 14,134 shares of the conglomerate’s stock valued at $1,193,000 after purchasing an additional 250 shares during the period. Hedge funds and other institutional investors own 75.49% of the company’s stock.

Danaher Corporation (DHR) opened at 91.81 on Tuesday. The stock’s 50 day moving average is $87.67 and its 200-day moving average is $84.50. The firm has a market capitalization of $63.78 billion, a PE ratio of 29.30 and a beta of 1.03. Danaher Corporation has a 52-week low of $76.27 and a 52-week high of $92.26.

Danaher Corporation (NYSE:DHR) last announced its quarterly earnings data on Thursday, October 19th. The conglomerate reported $1.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.05. The business had revenue of $4.53 billion for the quarter, compared to the consensus estimate of $4.47 billion. Danaher Corporation had a net margin of 13.36% and a return on equity of 11.29%. Danaher Corporation’s quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter last year, the company posted $0.87 earnings per share. Equities analysts expect that Danaher Corporation will post $3.99 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 27th. Stockholders of record on Friday, September 29th were paid a $0.14 dividend. The ex-dividend date of this dividend was Thursday, September 28th. This represents a $0.56 annualized dividend and a dividend yield of 0.61%. Danaher Corporation’s payout ratio is 16.52%.

ILLEGAL ACTIVITY WARNING: “Barings LLC Holds Position in Danaher Corporation (DHR)” was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://theolympiareport.com/2017/10/31/barings-llc-holds-position-in-danaher-corporation-dhr.html.

In other news, CFO Daniel L. Comas sold 88,184 shares of the firm’s stock in a transaction on Monday, October 23rd. The shares were sold at an average price of $91.02, for a total value of $8,026,507.68. Following the sale, the chief financial officer now owns 227,816 shares in the company, valued at $20,735,812.32. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Donald J. Ehrlich sold 10,578 shares of the firm’s stock in a transaction on Tuesday, October 24th. The stock was sold at an average price of $90.82, for a total transaction of $960,693.96. Following the completion of the sale, the director now owns 104,621 shares in the company, valued at approximately $9,501,679.22. The disclosure for this sale can be found here. In the last 90 days, insiders sold 153,639 shares of company stock worth $13,632,773. 12.20% of the stock is currently owned by corporate insiders.

A number of equities research analysts recently issued reports on DHR shares. Zacks Investment Research downgraded shares of Danaher Corporation from a “buy” rating to a “hold” rating in a report on Thursday, July 27th. Goldman Sachs Group, Inc. (The) restated a “neutral” rating and issued a $83.00 target price on shares of Danaher Corporation in a report on Tuesday, September 26th. Credit Suisse Group boosted their target price on shares of Danaher Corporation from $93.00 to $96.00 and gave the company an “outperform” rating in a report on Friday, October 20th. BidaskClub upgraded shares of Danaher Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, July 19th. Finally, J P Morgan Chase & Co reiterated an “overweight” rating and set a $95.00 price objective on shares of Danaher Corporation in a research note on Friday, September 8th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. Danaher Corporation currently has a consensus rating of “Buy” and an average target price of $93.31.

Danaher Corporation Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR).

Institutional Ownership by Quarter for Danaher Corporation (NYSE:DHR)

Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.